Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | IDH2 | P48735 | 2/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593089 | 0.91 | EPHB4 (0.54) | CYP1A2CYP2C19EPHB4KDRTEK | |
| SCHEMBL5585998 | 0.87 | KMT2A (0.46) | EPHB4KDRTEKKMT2APOLB | |
| SCHEMBL9885292 | 0.86 | TRPV1 (0.44) | EPHB4KDRTEKTRPV1PTGER3 | |
| SCHEMBL5612143 | 0.86 | EPHB4 (0.52) | EPHB4KDRTEKTRPV1PTGER3 | |
| SCHEMBL5586075 | 0.83 | KDR (0.47) | CYP1A2CYP2C19EPHB4KDRTEK | |
| SCHEMBL5586072 | 0.82 | KDR (0.47) | CYP1A2CYP2C19EPHB4KDRTEK | |
| SCHEMBL5592888 | 0.81 | EPHB4 (0.54) | EPHB4KDRTEKKMT2ATRPV1 | |
| SCHEMBL5592620 | 0.80 | EPHB4 (0.47) | EPHB4KDRTEKKMT2ATRPV1 | |
| SCHEMBL5671277 | 0.80 | EPHB4 (0.49) | EPHB4KDRTEKKMT2ATRPV1 | |
| SCHEMBL5592697 | 0.80 | EPHB4 (0.47) | EPHB4KDRTEKKMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | CYP1A2 2704/4885CYP2C9 2371/4885CYP2C19 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.